HC Wainwright assumed coverage on shares of Outlook Therapeutics (NASDAQ:OTLK) in a research note published on Thursday morning, Benzinga reports. The firm issued a buy rating and a $8.00 price objective on the stock.
Other equities analysts have also recently issued reports about the company. ValuEngine upgraded XPO Logistics from a strong sell rating to a sell rating in a research note on Thursday, April 4th. Oppenheimer began coverage on Outlook Therapeutics in a research note on Thursday, May 16th. They set an outperform rating and a $12.00 price objective on the stock. Ascendiant Capital Markets began coverage on Graham in a research note on Monday, April 22nd. They set a buy rating and a $1.59 price objective on the stock. Finally, CIBC restated a hold rating and set a $3.00 price objective on shares of Information Services Group in a research note on Thursday, May 16th. One investment analyst has rated the stock with a hold rating and four have assigned a buy rating to the stock. Outlook Therapeutics currently has an average rating of Buy and an average price target of $9.00.
Shares of NASDAQ:OTLK opened at $2.45 on Thursday. The company’s fifty day moving average is $2.15. Outlook Therapeutics has a 1-year low of $0.85 and a 1-year high of $10.96.
An institutional investor recently bought a new position in Outlook Therapeutics stock. Chicago Capital LLC purchased a new position in Outlook Therapeutics, Inc. (NASDAQ:OTLK) during the 2nd quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor purchased 19,450 shares of the company’s stock, valued at approximately $40,000. Chicago Capital LLC owned 0.07% of Outlook Therapeutics as of its most recent SEC filing. Institutional investors own 0.79% of the company’s stock.
Outlook Therapeutics Company Profile
Outlook Therapeutics, Inc, a late clinical-stage biopharmaceutical company, focuses on developing and commercializing monoclonal antibody for various ophthalmic indications. Its lead product candidate is ONS-5010, a proprietary ophthalmic bevacizumab product candidate that is in first clinical trial for the treatment of wet age related macular degeneration and other retina diseases.
Recommended Story: Investing in Growth Stocks
Receive News & Ratings for Outlook Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Outlook Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.